プラスミノーゲン市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、用途別、地域別、競合別、2020～2030年

世界のプラスミノーゲン市場は、2024年には26億5,000万米ドルと評価され、2030年にはCAGR5.43％を反映して36億4,000万米ドルに達すると予測されています。

プラスミノーゲンに基づく治療法は、特に創傷治癒や眼疾患など、様々な病態の治療法として認知されつつあり、市場は大きな勢いを増しています。線溶に関与する重要なタンパク質であるプラスミノーゲンは、血栓の分解や創傷治癒の促進に不可欠です。糖尿病性足潰瘍の原因となることが多い糖尿病などの慢性疾患の有病率の上昇が、プラスミノーゲンをベースとした治療に対する需要を牽引しています。さらに、バイオテクノロジーの進歩や、プラスミノーゲン治療に焦点を当てた臨床試験の増加が、その治療可能性への自信を強めています。現在進行中の調査により、その用途が明らかになりつつあり、木部結膜炎や慢性創傷などの症状に多様な治療オプションを提供することで、市場は大きく成長すると予想されます。

プラスミノーゲン市場の急成長に寄与する主な要因としては、個別化医療の台頭や新興国におけるヘルスケアインフラの拡大などが挙げられます。ヘルスケアの進化に伴い、個別化された治療計画が重視されるようになり、プラスミノーゲン治療の採用が増加すると予想されます。また、特にアジア太平洋やラテンアメリカなどの地域では、ヘルスケアへの投資が市場成長の原動力となっています。世界の外科手術の増加とそれに伴う術後ケアの必要性が、特に創傷ケアや組織再生におけるプラスミノーゲン療法の需要を高めています。さらに、臨床試験での有望な結果が投資家の関心を集め、継続的な技術革新とプラスミノーゲンベースの製品開発に拍車をかけています。

しかし、プラスミノーゲン市場は、その成長軌道を阻害しかねないいくつかの課題に直面しています。主な障害の一つは、プラスミノーゲンに基づく治療薬の製造コストが高いことで、特に低所得国での利用が制限される可能性があります。新しいプラスミノーゲン治療に対する厳格な承認プロセスを含む規制上の課題も、革新的なソリューションを導入しようとする企業にとって障壁となっています。このような課題にもかかわらず、現在進行中の臨床的進歩や効果的な創傷治癒ソリューションに対する需要の高まりは、主要な市場参入企業にとって大きな成長機会となります。治療コストの削減や承認プロセスの合理化への取り組みがこれらの課題に対処し、市場の可能性をさらに高めると期待されます。

主な市場促進要因

血栓関連疾患の有病率の上昇

主要市場の課題：

高い治療費

主な市場動向：

規制支援と臨床試験

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のプラスミノーゲン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（静脈注射、点眼薬）
  • 用途別（木質結膜炎、糖尿病性足病、創傷治癒、その他）
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 用途別
  • 地域別

第5章 アジア太平洋地域のプラスミノーゲン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のプラスミノーゲン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のプラスミノーゲン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のプラスミノーゲン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのプラスミノーゲン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のプラスミノーゲン市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Boehringer Ingelheim Inc. GmbH
• Kedrion S.p.A
• Genentech
• Prometic Life Sciences Inc
• Grifols, S.A
• Octapharma AG
• Green Cross Corporation
• Baxter International Inc.
• CSL Behring LLC
• Renaissance Acquisition Holdings LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

The global plasminogen market was valued at USD 2.65 billion in 2024 and is projected to reach USD 3.64 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.43%. The market is gaining considerable momentum due to the growing recognition of plasminogen-based therapies for treating a variety of medical conditions, particularly in wound healing and ocular diseases. Plasminogen, a crucial protein involved in fibrinolysis, is essential for breaking down blood clots and promoting wound healing. The rising prevalence of chronic diseases, such as diabetes, which often leads to diabetic foot ulcers, is driving the demand for plasminogen-based treatments. Additionally, advancements in biotechnology and the increasing number of clinical trials focusing on plasminogen therapies are bolstering confidence in its therapeutic potential. With ongoing research highlighting its applications, the market is expected to grow significantly, offering diverse treatment options for conditions like ligneous conjunctivitis and chronic wounds.

Key factors contributing to the rapid growth of the plasminogen market include the rise of personalized medicine and the expansion of healthcare infrastructure in emerging economies. As healthcare evolves, there is a greater focus on individualized treatment plans, which is anticipated to increase the adoption of plasminogen therapies. Additionally, investments in healthcare, especially in regions such as Asia-Pacific and Latin America, are driving market growth. The global rise in surgical procedures and the subsequent need for post-operative care have increased the demand for plasminogen therapies, particularly in wound care and tissue regeneration. Moreover, promising results in clinical trials have attracted investor interest, fueling continued innovation and the development of plasminogen-based products.

However, the plasminogen market faces several challenges that may impede its growth trajectory. One major obstacle is the high cost of manufacturing plasminogen-based therapies, which could limit their accessibility, particularly in low-income countries. Regulatory challenges, including rigorous approval processes for new plasminogen treatments, also present barriers for companies seeking to introduce innovative solutions. Despite these challenges, ongoing clinical advancements and the growing demand for effective wound healing solutions provide substantial growth opportunities for key market players. Efforts to reduce treatment costs and streamline the approval process are expected to address these challenges and further enhance the market's potential.

Key Market Drivers:

Rising Prevalence of Clot-Related Disorders

The increasing prevalence of clot-related disorders is a significant driver of the global plasminogen market. Conditions such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) have become more common due to factors such as sedentary lifestyles, rising obesity rates, and an aging population. In India, the incidence of DVT is reported to be 1% among adults over 40, with 15% to 20% of hospitalized patients affected. These disorders, which result from the abnormal formation of blood clots, can lead to serious complications like stroke, heart attacks, and respiratory failure, making timely treatment essential.

Plasminogen plays a key role in preventing or resolving clot-related complications. A deficiency or dysfunction of plasminogen can impede the body's ability to dissolve clots, increasing the risk of thrombotic events. As these disorders become more prevalent, the demand for plasminogen-based therapies to manage these life-threatening conditions is rising. Treatments involving plasminogen help dissolve existing clots and prevent new ones, improving patient outcomes and reducing complications. The growing number of diagnoses, coupled with improved diagnostic techniques and greater awareness, has expanded the patient base seeking effective treatment. This has led pharmaceutical companies to invest significantly in developing innovative plasminogen therapies, including recombinant plasminogen products, to address the growing demand for safe and effective clot management solutions.

Key Market Challenges:

High Treatment Costs

The high treatment costs associated with plasminogen-based therapies present a significant challenge to ensuring equitable access. The complex production of recombinant plasminogen products contributes to their elevated prices. The biotechnology processes involved in synthesizing plasminogen require sophisticated equipment, specialized expertise, and stringent quality control measures. Research, development, and manufacturing costs are substantial, and these expenses are often passed on to patients and healthcare systems.

Additionally, regulatory requirements add to the overall cost. Companies must invest significantly in preclinical and clinical trials to demonstrate the safety and efficacy of plasminogen treatments, meeting the rigorous standards set by regulatory agencies such as the FDA and EMA. These trials involve extensive data collection and monitoring, further contributing to the cost.

The limited patient pool also drives up treatment costs. While clot-related disorders are prevalent, they do not affect as large a population as other medical conditions, preventing the economies of scale that could reduce production costs for plasminogen therapies.

Key Market Trends:

Regulatory Support and Clinical Trials

Regulatory support and clinical trials are crucial drivers for the growth of the global plasminogen market. Regulatory agencies such as the FDA and EMA play an essential role in ensuring the safety and efficacy of plasminogen-based therapies, providing the necessary frameworks for drug approval and market entry. In India, the Central Drugs Standard Control Organization (CDSCO) has expedited the approval of critical therapies, including novel plasminogen replacement treatments for congenital plasminogen deficiency.

Clinical trials form the foundation for the development of plasminogen therapies, providing the evidence needed to validate their safety and effectiveness. As the number of clinical trials increases, so does the confidence in plasminogen's potential, both among healthcare providers and regulatory agencies. In 2024, the Clinical Trials Registry - India (CTRI) reported a 15% increase in registered clinical trials for plasminogen therapies. Notably, a Phase III trial aimed at evaluating recombinant plasminogen for chronic venous leg ulcers is underway, further demonstrating the commitment to advancing plasminogen-based therapies.

The support from regulatory bodies like the FDA, EMA, and CDSCO is instrumental in expediting the approval process and ensuring the continued development and accessibility of plasminogen therapies, ultimately improving patient outcomes.

Key Market Players:

• Boehringer Ingelheim Inc. GmbH
• Kedrion S.p.A
• Genentech
• Prometic Life Sciences Inc.
• Grifols, S.A.
• Octapharma AG
• Green Cross Corporation
• Baxter International Inc.
• CSL Behring LLC
• Renaissance Acquisition Holdings LLC

Report Scope:

The report segments the global plasminogen market as follows:

By Type:

• Intravenous Injection
• Eye Drops

By Application:

• Ligneous Conjunctivitis
• Diabetic Foot
• Wound Healing
• Others

By Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report provides a detailed analysis of key players in the global plasminogen market. Customizations are available to tailor the report to specific company needs, including additional profiling of up to five market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Plasminogen Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Intravenous Injection, Eye Drops)
  • 4.2.2. By Application (Ligneous Conjunctivitis, Diabetic Foot, Wound Healing, Others)
  • 4.2.3. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Application
  • 4.3.3. By Region

5. Asia Pacific Plasminogen Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Application
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Plasminogen Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Application
  • 5.3.2. India Plasminogen Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Application
  • 5.3.3. Australia Plasminogen Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Application
  • 5.3.4. Japan Plasminogen Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Application
  • 5.3.5. South Korea Plasminogen Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Application

6. Europe Plasminogen Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Plasminogen Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Germany Plasminogen Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Spain Plasminogen Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Italy Plasminogen Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Application
  • 6.3.5. United Kingdom Plasminogen Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Application

7. North America Plasminogen Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Plasminogen Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Mexico Plasminogen Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Canada Plasminogen Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application

8. South America Plasminogen Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Plasminogen Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Argentina Plasminogen Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Colombia Plasminogen Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application

9. Middle East and Africa Plasminogen Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Plasminogen Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Saudi Arabia Plasminogen Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. UAE Plasminogen Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Plasminogen Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Boehringer Ingelheim Inc. GmbH
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Kedrion S.p.A
• 14.3. Genentech
• 14.4. Prometic Life Sciences Inc
• 14.5. Grifols, S.A
• 14.6. Octapharma AG
• 14.7. Green Cross Corporation
• 14.8. Baxter International Inc.
• 14.9. CSL Behring LLC
• 14.10.Renaissance Acquisition Holdings LLC

15. Strategic Recommendations

16. About Us & Disclaimer